Relay Therapeutics, Inc.
NASDAQ:RLAYBiotechnology
+$0.41 today
- Market cap
- $3.65B
- Beta
- 1.75
- P/E (TTM)
- -10.5
- EPS (TTM)
- -$1.52
Volume 2.43M
Average 3.70M
RLAY Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Relay Therapeutics, Inc.NASDAQ: RLAY
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $76.48M rose 19.7% year over year, ahead of the -4.1% change in trailing-twelve-month research & development. Sequentially, it rose 8.4% from the prior quarter. Over 3 fiscal years it compounded at +2.0% a year.
Context
- Research & development amounted to 1702.3% of revenue in FY2025, down 1486.4 pp from a year earlier.
- Research & development increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +19.7% holds above the trailing-twelve-month pace of -4.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 261.38M USD
- Year-over-year change
- -18.1%
- 4-year CAGR
- -3.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 261.38M | -18.1% |
| FY2024 | 2024-12-31 | 319.09M | -3.3% |
| FY2023 | 2023-12-31 | 330.02M | +34.0% |
| FY2022 | 2022-12-31 | 246.36M | -16.7% |
| FY2021 | 2021-12-31 | 295.65M | — |
Research & Development vs competitors
How RLAY compares with its peers on the latest reported figures
- RLAY's LTM Jun 2026 research & development of $270.72M is the 5th highest of the 11 companies compared; the peer median is $143.04M.
- Its year-over-year change of -4.1% is the 10th highest of 11, against a peer median of +12.3%.
- Research & development amounts to 2615.7% of revenue for RLAY, versus a peer median of 254.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.29B | +68.1% | +57.0% | — | |
| LTM Jun 2026 | $375.6M | +29.1% | +24.5% | 357.8% | |
| LTM Mar 2026 | $339.54M | +5.2% | +52.0% | 150.7% | |
| LTM Aug 2026 | $331.95M | +10.2% | +18.6% | 47.3% | |
| LTM Jun 2026 | $270.72M | -4.1% | +2.0% | 2615.7% | |
| LTM Sep 2026 | $152.48M | +14.3% | +7.7% | — | |
| LTM Sep 2026 | $133.6M | +39.6% | -6.2% | — | |
| LTM Mar 2026 | $129.68M | +5.2% | +71.4% | — | |
| LTM Mar 2026 | $116.62M | -0.1% | +21.2% | — | |
| LTM Mar 2026 | $111.3M | +26.9% | +33.8% | — | |
| LTM Mar 2026 | $79.09M | -33.8% | +0.5% | 473.0% | |
| Peer median (excluding RLAY) | $143.04M | +12.3% | +22.8% | 254.2% | |
Competitors are the stored peer set for RLAY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 3.03M | 1.38M | 25.55M | 10.01M | 15.36M |
| Cost of Revenue | 169.39M | 243.01M | 326.39M | 315.44M | 3.56M |
| Gross Profit | (166.36M) | (241.62M) | (300.84M) | (305.43M) | 11.8M |
| Gross Margin | -5492.2% | -17496.3% | -1177.6% | -3052.2% | 76.8% |
| Research & Development | 295.65M | 246.36M | 330.02M | 319.09M | 261.38M |
| Selling, General & Admin | 59.75M | 69.33M | 78.58M | 80.24M | 56.71M |
| Operating Expenses | 198.34M | 57.65M | 72.16M | 67.03M | 314.54M |
| Depreciation & Amortization | 3.93M | 4.13M | 5.27M | 5.46M | 3.56M |
| EBITDA | (223.08M) | (306.82M) | (374.15M) | (380.21M) | (272.92M) |
| EBITDA Margin | -7364.9% | -22217.4% | -1464.6% | -3799.4% | -1777.4% |
| Operating Income | (364.7M) | (299.28M) | (373M) | (372.47M) | (302.74M) |
| Operating Margin | -12040.2% | -21670.9% | -1460.1% | -3722.1% | -1971.6% |
| Interest Income | 830K | 8.79M | 31.05M | 34.75M | 27.04M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 826K | 8.77M | 31.03M | 34.76M | 26.26M |
| Income Before Tax | (363.87M) | (290.51M) | (341.97M) | (337.71M) | (276.48M) |
| Pre-Tax Margin | -12012.9% | -21036.1% | -1338.7% | -3374.7% | -1800.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (363.87M) | (290.51M) | (341.97M) | (337.71M) | (276.48M) |
| Net Margin | -12012.9% | -21036.1% | -1338.7% | -3374.7% | -1800.6% |
| EPS (Basic) | (3.82) | (2.59) | (2.79) | (2.36) | (1.61) |
| EPS (Diluted) | (3.82) | (2.59) | (2.79) | (2.36) | (1.61) |
| Weighted Avg Shares | 95.14M | 112.23M | 122.58M | 142.87M | 171.59M |
| Weighted Avg Shares (Diluted) | 95.14M | 112.23M | 122.58M | 142.87M | 171.59M |
Relay Therapeutics, Inc.
NASDAQ:RLAY
Intrinsic Alpha fair value
Locked
Current Price
$16.51
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.